Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD
Status:
Completed
Trial end date:
2016-06-30
Target enrollment:
Participant gender:
Summary
Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease
surrogate markers of bone metabolism and early cardiovascular disease in individuals with
moderate to severe airflow obstruction and a chronic bronchitis phenotype.